4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow [Yahoo! Finance]
4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023) [Yahoo! Finance]
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights [Yahoo! Finance]
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights